XCUR Exicure Inc
- Stocks
- Healthcare
- NASDAQ: XCUR
Price (delayed)
$6.8858
Market cap
$43.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.82
Enterprise value
$33.11M
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes its proprietary
Highlights
The debt has plunged by 100% YoY and by 99% from the previous quarter
XCUR's equity has soared by 68% since the previous quarter
XCUR's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
XCUR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of XCUR
Market
Valuations
Earnings
Shares outstanding
6.32M
Market cap
$43.5M
Enterprise value
$33.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$8.45M
Net income
-$5.86M
EBIT
-$5.84M
EBITDA
-$5.11M
Free cash flow
-$4.06M
Per share
Balance sheet
Liquidity
EPS
-$3.82
EPS diluted
-$3.82
Free cash flow per share
-$0.66
Book value per share
$1.8
Revenue per share
$0
TBVPS
$2.2
Total assets
$20.68M
Total liabilities
$9.3M
Debt
$27,000
Equity
$11.38M
Working capital
$7.42M
Debt to equity
0
Current ratio
2.91
Quick ratio
2.72
Net debt/EBITDA
2.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41.1%
Return on equity
-110%
Return on invested capital
-79.4%
Return on capital employed
-34.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XCUR stock price
How has the Exicure stock price performed over time
Intraday
-3.42%
1 week
-12.31%
1 month
12.88%
1 year
178.78%
YTD
-49.63%
QTD
-2.19%
Financial performance
How have Exicure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.45M
Net income
-$5.86M
Gross margin
N/A
Net margin
N/A
XCUR's gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
XCUR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The net income has soared by 56% year-on-year and by 40% since the previous quarter
XCUR's operating income is up by 31% since the previous quarter and by 25% year-on-year
Price vs fundamentals
How does XCUR's price correlate with its fundamentals
Growth
What is Exicure's growth rate over time
Valuation
What is Exicure stock price valuation
P/E
N/A
P/B
3.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Exicure's EPS has increased by 50% YoY and by 20% from the previous quarter
XCUR's equity has soared by 68% since the previous quarter
XCUR's P/B is 13% below its last 4 quarters average of 4.4 but 12% above its 5-year quarterly average of 3.4
XCUR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Exicure business performance
XCUR's ROE has soared by 66% QoQ and by 60% YoY
The ROA has soared by 59% YoY and by 50% from the previous quarter
Exicure's ROIC has increased by 10% from the previous quarter and by 4.7% YoY
Dividends
What is XCUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XCUR.
Financial health
How did Exicure financials performed over time
The company's total assets is 122% higher than its total liabilities
The company's total assets has surged by 93% YoY and by 37% QoQ
The quick ratio has contracted by 36% from the previous quarter
The debt is 100% less than the equity
The debt has plunged by 100% YoY and by 99% from the previous quarter
Exicure's debt to equity has shrunk by 100% QoQ and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.